Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $32.74 USD
Change Today -0.36 / -1.09%
Volume 57.9K
PMC On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 1:30 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

pharmerica corp (PMC) Key Developments

PharMerica Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Outlook for the Third Quarter of 2015; Reaffirms Earnings Guidance for the Full Year 2015

PharMerica Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $497.5 million against $448.6 million a year ago. Operating loss was $8.5 million against operating loss of $9.7 million a year ago. Income before income taxes was $6.6 million against loss before income taxes of $12.0 million a year ago. Net income was $2.3 million against net loss of $9.7 million a year ago. Diluted net income per share was $0.07 against loss per share of $0.32 a year ago. Adjusted EBITDA was $33.2 million against $30.6 million a year ago, up by 8.5%. Adjusted diluted earnings per share were $0.37 against $0.40 a year ago, down by 7.5%. Cash flows used in operating activities were $22.2 million compared with $26.5 million a year ago. Purchase of equipment and leasehold improvements was $6.4 million against $6.8 million a year ago. The increase in revenue was driven by recent acquisitions, growth in the company's specialty pharmacy businesses and branded drug inflation. For the six months, the company reported revenues of $1,009.0 million against $900.8 million a year ago. Operating income was $25.3 million against operating loss of $0.6 million a year ago. Income before income taxes was $22.0 million against loss before income taxes of $4.2 million a year ago. Net income was $11.9 million against net loss of $4.9 million a year ago. Diluted net income per share was $0.38 against loss per share of $0.16 a year ago. Cash flows provided by operating activities were $22.1 million compared with cash flows used in operating activities of $22.1 million for the same period last year. The increase in cash from operating activities was due primarily to the $48.8 million in AmerisourceBergen Drug Corporation drug purchase payments withheld, the corporation’s inventory purchasing strategy and an increase in net income, which were partially offset by an increase in AmerisourceBergen Drug Corporation rebates receivable. Purchase of equipment and leasehold improvements was $11.0 million against $12.8 million a year ago. Adjusted EBITDA was $70.6 million against $60.3 million a year ago, up by 8.5% Adjusted diluted earnings per share was $0.85 against $0.77 a year ago. For the third quarter of 2015, the company provided guidance as follows: revenue in the range of $470 million to $480 million; adjusted diluted earnings per share in the range of $0.36 to $0.37; and adjusted EBITDA in the range of $32 million to $33 million. The company reaffirms its full year 2015 guidance metrics: revenue in the range of $1.950 billion to $2.050 billion; adjusted diluted earnings per share in the range of $1.55 to $1.65; and adjusted EBITDA in the range of $137 million to $142 million.

PharMerica Seeks Acquisitions

Greg Weishar, PharMerica Corporation (NYSE:PMC)'s Chief Executive Officer, said, "PharMerica's strong, scalable national platform is built to support continued growth. In the second half of 2015 we will stay focused on driving organic growth, diversifying the revenue base through prudent acquisitions and building scale. We are confident this strategy enables PharMerica to continue creating value for our shareholders, clients and patients."

PharMerica Corporation to Report Q2, 2015 Results on Aug 07, 2015

PharMerica Corporation announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Aug 07, 2015

PharMerica Corporation, Q2 2015 Earnings Call, Aug 07, 2015

PharMerica Corporation, Q2 2015 Earnings Call, Aug 07, 2015

PharMerica Reportedly Can Be The Target Of The Next Big Healthcare Deal

People in the investment banking and healthcare industries speculate that PharMerica Corporation (NYSE:PMC) will soon be acquired. PharMerica's shares are up more than 50% in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PMC:US $32.74 USD -0.36

PMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
SunLink Health Systems Inc $1.75 USD +0.0904
View Industry Companies
 

Industry Analysis

PMC

Industry Average

Valuation PMC Industry Range
Price/Earnings 43.6x
Price/Sales 0.5x
Price/Book 2.0x
Price/Cash Flow 20.7x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMERICA CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.